Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Ueda, Japan Clinical Trials

A listing of Ueda, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (4) clinical trials

Evaluation of ALX-0171 in Japanese Children Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection

The objectives of this study are: to evaluate the safety, tolerability, and systemic pharmacokinetics (PK) of different doses of inhaled ALX-0171 in Japanese infants and young children hospitalized for respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI). to evaluate the antiviral effect, clinical activity, immunogenicity, and pharmacodynamics (PD) of ...

Phase

0.0 miles

Learn More »

A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease

This is an international, multicentre, event-driven, randomized, double-blind, parallel group, placebo-controlled study, evaluating the effect of dapagliflozin versus placebo, given once daily in addition to standard of care, to prevent the progression of chronic kidney disease (CKD) or cardiovascular (CV)/renal death.

Phase

0.78 miles

Learn More »

Maintenance Treatment of Renal Anemia in Dialysis Subjects

The purpose of this study is to evaluate the efficacy and safety of molidustat in comparison to darbepoetin alfa in dialysis subjects with renal anemia who are treated with Erythropoiesis-Stimulating Agents (ESAs).

Phase

5.06 miles

Learn More »

Study Assessing the Safety Tolerability and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia in 2 Parts (Part 1 and 2).

This multicenter study will be conducted in 2 parts (Part 1 and 2). This is an ascending multiple oral dose, open-label study assessing the safety, tolerability, and pharmacokinetics of SEP-363856 in male and female subjects with schizophrenia. In part 1, subjects will have up to two visits, including a screening ...

Phase

5.37 miles

Learn More »